Ahn Eric S, Subramanian Prem S
Department of Ophthalmology, Wilmer Eye Institute, The Johns Hopkins University School of Medicine, 600 N Wolfe St, Woods 457, Baltimore MD 21287, USA.
Indian J Ophthalmol. 2014 Oct;62(10):999-1002. doi: 10.4103/0301-4738.145994.
The aim was to highlight recent advances in the treatment of thyroid eye disease.
Review article.
Existing literature and the authors' experience was reviewed.
Thyroid ophthalmopathy is a disfiguring and vision-threatening complication of autoimmune thyroid disease that may develop or persist even in the setting of well-controlled systemic thyroid status. Treatment response can be difficult to predict, and optimized algorithms for disease management do not exist. Thyroid ophthalmopathy should be graded for both severity and disease activity before choosing a treatment modality for each patient. The severity of the disease may not correlate directly with the activity; medical treatment is most effective in active disease, and surgery is usually reserved for quiescent disease with persistent proptosis and/or eyelid changes.
Intravenous pulsed corticosteroids, orbital radiotherapy, and orbital surgical techniques form the mainstay of current management of thyroid ophthalmopathy. Immunosuppressive and biologic agents may have a role in treating active disease although additional safety and efficacy studies are needed.
旨在强调甲状腺眼病治疗方面的最新进展。
综述文章。
回顾现有文献及作者经验。
甲状腺眼病是自身免疫性甲状腺疾病一种毁容且威胁视力的并发症,即使在全身性甲状腺状态得到良好控制的情况下也可能发生或持续存在。治疗反应难以预测,且不存在用于疾病管理的优化算法。在为每位患者选择治疗方式之前,应根据严重程度和疾病活动度对甲状腺眼病进行分级。疾病的严重程度可能与活动度无直接关联;药物治疗在活动性疾病中最为有效,而手术通常用于患有持续性眼球突出和/或眼睑改变的静止期疾病。
静脉注射脉冲式皮质类固醇、眼眶放疗和眼眶手术技术构成了当前甲状腺眼病治疗的主要手段。免疫抑制剂和生物制剂在治疗活动性疾病中可能发挥作用,不过还需要更多安全性和有效性研究。